MiNK Therapeutics Says First Patients In Randomized Phase 2 C-1300-02 Trial Of agenT-797 Alive At Day 28 With Improved Oxygenation, ARDS Resolution, Vasopressor Liberation

MiNK Therapeutics Q2 2026 Earnings Call: Complete Transcript

MiNK Therapeutics (NASDAQ:INKT) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs. For real-time access to

8-K filing — MiNK Therapeutics, Inc. (INKT)

Filed: 2026-08-13 AccNo: 0001193125-26-347907 Size: 215 KB Item 2.02: Results of Operations and Financial Condition

MiNK Therapeutics Announces Launch Of Paid International Named-Patient Access Program For agenT-797 In Brazil With Orphan Drug Consulting